Larimar Therapeutics (LRMR) EBITDA (2013 - 2025)
Larimar Therapeutics (LRMR) posted EBITDA of -$64.0 million for Q4 2025, down 29.33% on a QoQ basis from -$49.5 million in Q3 2025, and down 104.58% year-over-year from $1.4 billion in Q4 2024.
Larimar Therapeutics (LRMR) EBITDA (2013 - 2025) Analysis & Trends
Larimar Therapeutics' EBITDA history runs 13 years deep, the most recent figure standing at -$64.0 million for Q4 2025.
- Quarterly EBITDA fell 104.58% year-over-year to -$64.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172.5 million (down 89.79% YoY) and the FY2025 annual result came in at -$172.5 million, down 89.79% from the prior year.
- EBITDA was -$64.0 million for Q4 2025 at Larimar Therapeutics, down from -$49.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$7.6 million in Q1 2023 and bottomed at -$64.0 million in Q4 2025.
- A 5-year average of -$19.6 million and a median of -$13.4 million in 2021 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA soared 49.12% — and 2025, when it slumped 171.02%.
- Larimar Therapeutics' EBITDA stood at -$9.1 million in 2021, then retreated by 14.89% to -$10.4 million in 2022, then plunged by 35.66% to -$14.2 million in 2023, then plunged by 120.96% to -$31.3 million in 2024, then tumbled by 104.58% to -$64.0 million in 2025.
- Business Quant data shows LRMR's EBITDA at -$64.0 million in Q4 2025, -$49.5 million in Q3 2025, and -$27.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Larimar Therapeutics | 36.71 Mn | -100.14 Mn | - | -64.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64.02 Mn |
| Sep 30, 2025 | -49.50 Mn |
| Jun 30, 2025 | -27.79 Mn |
| Mar 31, 2025 | -31.19 Mn |
| Dec 31, 2024 | -31.29 Mn |
| Sep 30, 2024 | -18.26 Mn |
| Jun 30, 2024 | -24.60 Mn |
| Mar 31, 2024 | -16.73 Mn |
| Dec 31, 2023 | -14.16 Mn |
| Sep 30, 2023 | -10.34 Mn |
| Jun 30, 2023 | -9.62 Mn |
| Mar 31, 2023 | -7.64 Mn |
| Dec 31, 2022 | -10.44 Mn |
| Sep 30, 2022 | -8.51 Mn |
| Jun 30, 2022 | -8.69 Mn |
| Mar 31, 2022 | -8.89 Mn |
| Dec 31, 2021 | -9.09 Mn |
| Sep 30, 2021 | -16.73 Mn |
| Jun 30, 2021 | -12.54 Mn |
| Mar 31, 2021 | -12.11 Mn |